Biosimilar therapeutic peptides market seen reaching $6.11 billion by 2030

Nov. 20, 2026
Biosimilar therapeutic peptides market seen reaching $6.11 billion by 2030
By AI, Created 15:30 UTC, Nov 20, 2026, AGP -

The biosimilar therapeutic peptides market reached $3.5 billion in 2025 and is projected to grow to $3.9 billion in 2026, according to The Business Research Company. The report points to rising chronic disease cases, broader peptide use in cancer and metabolic care, and new delivery formats as the main forces behind the expansion.

Why it matters: - The biosimilar therapeutic peptides market is growing as health systems look for lower-cost treatment options for chronic and complex diseases. - The market could help widen access to peptide-based therapies in oncology, metabolic disease, cardiovascular care and other areas. - Rising demand matters because chronic disease treatment often requires long-term spending and sustained drug supply.

What happened: - The Business Research Company released its Biosimilar Therapeutic Peptides Global Market Report 2026 covering market size, trends and forecasts through 2035. - The report says the market reached $3.5 billion in 2025. - The market is projected to grow to $3.9 billion in 2026, a 11.5% compound annual growth rate. - The report forecasts the market will reach $6.11 billion by 2030, with a 11.9% CAGR. - North America held the largest market share in 2025. - The Middle East is expected to be the fastest-growing region during the forecast period.

The details: - Growth in 2025 and 2026 is linked to limited availability of biosimilar peptides, continued reliance on innovative peptide therapies and rising cases of cancer and metabolic disorders. - Broader awareness of peptide treatments and advances in parenteral delivery methods also support the near-term outlook. - Longer-term growth is tied to combination and long-acting peptides, wider production of generic peptides and greater use of transdermal delivery systems. - The report also points to rising investment in peptide research and development and higher healthcare spending on peptide-based therapeutics. - Key therapeutic areas include cancer, metabolic diseases, pulmonary conditions, cardiovascular disorders and other illnesses. - The report includes regional coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America and Africa. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based dashboards, market hotspot infographics, and updated technology and trend analysis. - A free sample is available here. - The full report is available here.

Between the lines: - The market outlook suggests biosimilar peptides are moving from a niche category toward broader clinical use as delivery options improve and costs come under pressure. - The emphasis on generic, long-acting and combination peptides signals a push for products that are easier to administer and more commercially scalable. - The report's regional split points to mature demand in North America and faster expansion potential in markets that are increasing healthcare investment. - CDC data cited in the report showed that in 2023, about 194 million U.S. adults, or 76.4% of the adult population, had at least one chronic condition. - The same data showed prevalence of 59.5% among young adults, 78.4% among middle-aged adults and 93.0% among older adults.

What's next: - The report expects more demand in oncology, metabolic and cardiovascular applications. - Wider adoption of parenteral and transdermal delivery routes is likely to shape product development. - Cost-effective generic peptides are expected to gain more traction in emerging markets. - The market is projected to keep expanding through 2030 as chronic disease burdens and healthcare spending rise.

The bottom line: - Biosimilar therapeutic peptides are on a strong growth path, with the market projected to nearly double from 2025 levels by 2030 as demand for affordable, long-term treatments expands.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

US Healthcare Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

US Healthcare Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.